author-photo

Florence Hourcade-Potelleret

Hoffmann-La Roche

12

Papers

214

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

First-in-Human, Phase I Dose-Escalation Study of CGM097, a HDM2 Inhibitor in Adult Patients With p53 Wild-type Advanced Solid Malignancies

2021
Show All
- Source
- Cite
- Save
Citations (0)
Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (17)
COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY: S883

2019
Show All
- Source
- Cite
- Save
Citations (5)
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

2016 Haematologica
Show All
- Source
- Cite
- Save
Citations (27)
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.

2015 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (25)
A Phase 1b Open-Label, Multicenter, Dose-Escalation and -Expansion Study of Orally Administered Binimetinib (MEK162) Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

2014
Show All
- Source
- Cite
- Save
Citations (0)
Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab

2014 Drug Research
Show All
- Source
- Cite
- Save
Citations (21)
Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

2012 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen.

2012 Drug Research
Show All
- Source
- Cite
- Save
Citations (38)
Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),

2011 Blood
Show All
- Source
- Cite
- Save
Citations (4)